Abstract Body

Cell-based gene therapy has quickly become the new frontier for treatment of HIV infection. Clinical trials have shown CD4 chimeric antigen receptor (CD4CAR) modified T cells to be moderately effective against HIV and safe when introduced through adoptive T cell transfer. This CAR expresses CD4 attached to an intracellular CD3 zeta-domain. When bound to the HIV envelope glycoprotein 120 (gp120), CD4 CAR expressing CD8 cells elicit an immune response against infected cells. Despite its success in vitro, T cells modified with the CD4 CAR showed limited efficacy against HIV infection in clinical trials. Studies suggest that CD4 CAR modified CD8 cells may have lost their efficiency due to their susceptibility to HIV infection via CD4 expression, excessive ex vivo activation and cell processing, and immune exhaustion/premorbidity. Thus, we aim to overcome these limitations to improve CD4CAR T cell therapy. We hypothesize that preventing exhaustion and infection in CAR expressing T cells will enhance antiviral response and efficacy against HIV infection in vivo.

To address these problems and attempt to improve CAR-driven T cell responses and prevent cellular infection, we constructed a truncated CD4 CAR molecule that contains solely the D1 and D2 domains of the CD4 molecule. In addition, we incorporated a PD-1 specific shRNA into the vector to knock down check-point inhibitor PD-1 expression on CAR modified cells to attempt to enhance their function. Humanized mice were constructed and infected with HIV and received autologous T cell transplants of modified CD4 and CD8 cells with either a control non-specific shRNA containing D1D2CD4CAR lentiviral vector or a PD1shRNA containing D1D2CD4CAR lentiviral vector.

We found that the D1D2CD4CAR maintains the HIV Env binding site but does not allow HIV infection when introduced into CD8 T cells. The PD-1 shRNA effectively knocked down PD-1 expression on modified T cells both in vitro and in vivo. Further, we found that the PD-1shRNA containing D1D2CD4CAR cells have improved function and proliferation. Mice that received PD1shRNA D1D2CD4CAR cells showed improved viral control as compared to mice that received control CAR modified T cells. 

Specific knockdown of PD-1 expression on CAR modified T cells can enhance anti-HIV efficacy and highlights the potential of targeting immune check point inhibitors to enhance T cell gene therapy.